Literature DB >> 21446779

Varespladib.

.   

Abstract

Anthera Pharmaceuticals is developing an oral formulation of varespladib (A 001; A 002; A-001; A-002; LY 315920; LY 333013; LY315920; LY333013; S 3013; S 5920; S-3013; S-5920; Varespladib methyl) for once-daily treatment of acute coronary syndromes. Varespladib acts by inhibiting secretory phospholipase A2 (sPLA2) and the drug is currently being evaluated in approximately 6500 patients with acute coronary syndromes receiving atorvastatin in the placebo-controlled VISTA 16 (NCT01130246) trial being conducted in North America and Europe. This review discusses the development history and scientific profile of this new compound.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21446779     DOI： 10.2165/11533650-000000000-00000

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN： 1175-3277            Impact factor:   3.571


  12 in total

Review 1.  Developing Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite.

Authors:  Tommaso C Bulfone; Stephen P Samuel; Philip E Bickler; Matthew R Lewin
Journal:  J Trop Med       Date:  2018-07-30

2.  Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920).

Authors:  Guilherme H M Salvador; Antoniel A S Gomes; Wendy Bryan-Quirós; Julián Fernández; Matthew R Lewin; José María Gutiérrez; Bruno Lomonte; Marcos R M Fontes
Journal:  Sci Rep       Date:  2019-11-20       Impact factor: 4.379

3.  A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite.

Authors:  Laura-Oana Albulescu; Chunfang Xie; Stuart Ainsworth; Jaffer Alsolaiss; Edouard Crittenden; Charlotte A Dawson; Rowan Softley; Keirah E Bartlett; Robert A Harrison; Jeroen Kool; Nicholas R Casewell
Journal:  Nat Commun       Date:  2020-12-15       Impact factor: 14.919

4.  Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation.

Authors:  Matthew Lewin; Stephen Samuel; Janie Merkel; Philip Bickler
Journal:  Toxins (Basel)       Date:  2016-08-25       Impact factor: 4.546

5.  Varespladib Inhibits the Phospholipase A2 and Coagulopathic Activities of Venom Components from Hemotoxic Snakes.

Authors:  Chunfang Xie; Laura-Oana Albulescu; Kristina B M Still; Julien Slagboom; Yumei Zhao; Zhengjin Jiang; Govert W Somsen; Freek J Vonk; Nicholas R Casewell; Jeroen Kool
Journal:  Biomedicines       Date:  2020-06-17

6.  PLA2 Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky's Viper Vipera berus nikolskii.

Authors:  Oleksandr Zinenko; Igor Tovstukha; Yevgen Korniyenko
Journal:  Toxins (Basel)       Date:  2020-05-29       Impact factor: 4.546

7.  Delayed LY333013 (Oral) and LY315920 (Intravenous) Reverse Severe Neurotoxicity and Rescue Juvenile Pigs from Lethal Doses of Micrurus fulvius (Eastern Coral Snake) Venom.

Authors:  Matthew R Lewin; Lyndi L Gilliam; John Gilliam; Stephen P Samuel; Tommaso C Bulfone; Philip E Bickler; José María Gutiérrez
Journal:  Toxins (Basel)       Date:  2018-11-17       Impact factor: 4.546

8.  Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus scutellatus) Venom.

Authors:  Matthew R Lewin; José María Gutiérrez; Stephen P Samuel; María Herrera; Wendy Bryan-Quirós; Bruno Lomonte; Philip E Bickler; Tommaso C Bulfone; David J Williams
Journal:  Toxins (Basel)       Date:  2018-09-20       Impact factor: 4.546

9.  Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms.

Authors:  José María Gutiérrez; Matthew R Lewin; David J Williams; Bruno Lomonte
Journal:  Toxins (Basel)       Date:  2020-02-20       Impact factor: 4.546

Review 10.  The Search for Natural and Synthetic Inhibitors That Would Complement Antivenoms as Therapeutics for Snakebite Envenoming.

Authors:  José María Gutiérrez; Laura-Oana Albulescu; Rachel H Clare; Nicholas R Casewell; Tarek Mohamed Abd El-Aziz; Teresa Escalante; Alexandra Rucavado
Journal:  Toxins (Basel)       Date:  2021-06-29       Impact factor: 4.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.